Snehal Patel Purchases 3,600 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 3,600 shares of the stock in a transaction dated Monday, April 7th. The stock was acquired at an average price of $9.10 per share, for a total transaction of $32,760.00. Following the completion of the transaction, the chief executive officer now directly owns 5,561,602 shares of the company’s stock, valued at approximately $50,610,578.20. The trade was a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Snehal Patel also recently made the following trade(s):

• On Friday, April 4th, Snehal Patel purchased 5,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $8.73 per share, for a total transaction of $48,015.00.
• On Friday, January 10th, Snehal Patel bought 2,500 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $12.51 per share, for a total transaction of $31,275.00.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $9.43 on Thursday. Greenwich LifeSciences, Inc. has a one year low of $8.06 and a one year high of $18.75. The company has a 50-day simple moving average of $11.34 and a 200-day simple moving average of $12.62. The firm has a market capitalization of $123.96 million, a PE ratio of -11.79 and a beta of 1.76.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Institutional Trading of Greenwich LifeSciences

Several hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its position in Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares during the last quarter. GAMMA Investing LLC bought a new stake in Greenwich LifeSciences in the 1st quarter valued at about $126,000. Bank of America Corp DE lifted its position in Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares during the last quarter. Northern Trust Corp lifted its position in Greenwich LifeSciences by 17.3% in the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock valued at $982,000 after purchasing an additional 12,923 shares during the last quarter. Finally, Barclays PLC lifted its position in Greenwich LifeSciences by 12.7% in the 4th quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after purchasing an additional 1,088 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.